From FT news.. Sanofi-Aventis’ all but hostile $18.5bn bid for Genzyme elicited the usual rejection drivel. The troubled US biotech believes it is undervalued by…
From FT news.. Sanofi-Aventis’ all but hostile $18.5bn bid for Genzyme elicited the usual rejection drivel. The troubled US biotech believes it is undervalued by…